https://www.thebodypro.com/category/adverse-events-comorbidities-hiv/tag/conference-coverage

The Latest

Will There Ever Be a Hepatitis C Vaccine? Img

Will There Ever Be a Hepatitis C Vaccine?

Amidst the clamor and excitement of the ongoing hepatitis C (HCV) treatment renaissance, one word is rarely uttered: vaccine. But the hunt goes on, quietly -- and with great difficulty.

Hepatitis C Regimen, 3D, Cures 99% of Patients, With or Without Ribavirin Img

Hepatitis C Regimen, 3D, Cures 99% of Patients, With or Without Ribavirin

An oral, interferon-free combination of three drugs (ABT-450, ombitasvir and dasabuvir), administered with or without ribavirin, achieved a sustained virologic response 12 weeks post treatment (SVR12) in 99% of patients with chronic hepatitis C.

Short-Term Weight Gain Associated With Increase in CVD and Diabetes Post-ART in HIV Cohort Img

Short-Term Weight Gain Associated With Increase in CVD and Diabetes Post-ART in HIV Cohort

Data from a large cohort reveal much variability in mean weight gains after initiating ART, depending on the weight category before going on treatment.

International Activists Confront Gilead Over Hepatitis C Drug Pricing at AIDS 2014 Img

International Activists Confront Gilead Over Hepatitis C Drug Pricing at AIDS 2014

An international group of treatment activists interrupted a session at AIDS 2014 just as Gregg H. Alton, a top official at Gilead Sciences, was about to speak regarding the challenges of expanding global access to the new generation of hepatitis C dr...

Activists Hold Die-In to Protest High Price of Gilead's Hepatitis C Drug Img

Activists Hold Die-In to Protest High Price of Gilead's Hepatitis C Drug

HCV drugs are priced out of reach and out of control.

-- Michel Sidibé, UNAIDS

MELBOURNE, Australia -- Treatment activists at the 20th International AIDS Conference held a die-in to protest the exorbitant pricing of Sovaldi (sofosbuvir), Gilead...

CROI 2014: Fair Pricing Coalition Seeks to Increase Access to HIV and HCV Treatment (Video) Img

CROI 2014: Fair Pricing Coalition Seeks to Increase Access to HIV and HCV Treatment (Video)

Lynda Dee of the Fair Pricing Coalition (FPC) spoke with coworkers Jeff Berry and Murray Penner, as well as David Evans of Project Inform, about access to HIV and hepatitis C (HCV) medications. FPC negotiates with pharmaceutical companies to make the...

CROI 2014: Research on HIV-Related Neurological Issues (Video) Img

CROI 2014: Research on HIV-Related Neurological Issues (Video)

IFARA sat down with Bruce Brew, Serena Spudich and Scott Letendre to talk about the HIV community's resurgent interest in neurology and the impact HIV itself might have on neurocognitive impairment. Issues discussed included the move from researching...

Looking Forward in Hepatitis C Treatment, With Trepidation Img

Looking Forward in Hepatitis C Treatment, With Trepidation

We may be at a dramatic turning point in our efforts to wipe out hepatitis C forever. "But we have to figure out how to bring the cure to the people," warns advocate Tracy Swan.

Abacavir Link to Cardiovascular Events in High-Risk Patients Maintained in D:A:D Study Img

Abacavir Link to Cardiovascular Events in High-Risk Patients Maintained in D:A:D Study

A poster at CROI 2014, presented by Caroline Sabin from University College London and colleagues, presented follow-up results from D:A:D since the initial findings in 2008 of a link between abacavir use and risk of myocardial infarction (MI) in peopl...

High Cure Rates for Short-Course Oral Hepatitis C Treatment Img

High Cure Rates for Short-Course Oral Hepatitis C Treatment

A new hepatitis C treatment regimen in development appears to have extremely high cure rates, despite only requiring a person to take pills for six weeks.